Observational Study on Patients With Hepatobiliary Tumors

  • STATUS
    Recruiting
  • End date
    Dec 1, 2023
  • participants needed
    1000
  • sponsor
    Gang Chen, MD
Updated on 26 January 2021

Summary

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans after surgery. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we obtained blood and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.

Description

This is an ongoing, longitudinal, single centre, observational clinical cohort study of patients with hepatobiliary tumors. All the patients are diagnosed, treated and followed up by The First Affiliate hospital of Wenzhou medical university.

Details
Condition Adenocarcinoma, Cholangiocarcinoma, Biliary neoplasm, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Malignant neoplasm of gallbladder, Gallbladder Disease, Gallbladder Carcinoma, Urothelial Tract Cancer, Gall Bladder Disorders, Liver Cancer, Malignant Adenoma, Gall Bladder Cancer, Biliary Tract Cancer, gallbladder cancer, liver cell carcinoma, biliary cancer
Clinical Study IdentifierNCT04637048
SponsorGang Chen, MD
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Be older than 18 years old
Clinical or pathological diagnosis of malignant hepatobiliary tumors
Patients have received or are about to receive surgery, chemotherapy radiotherapy, targeted therapy, local therapy, immunotherapy, etc
Patients understand and are willing to sign written informed consent

Exclusion Criteria

Patients considered by the doctor to be unsuitable for entry into this study (mental disorder or poor compliance, etc.)
The patient or guardian is unwilling to participate in this study
Pregnant women
Combined with other serious systemic diseases (heart failure, renal failure,hematopoietic system disease or Uncontrollable acute infection)
Estimated survival time is less than 1 month
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note